Rejoinder to "Establishing efficacy of a new experimental treatment in the 'gold standard' design"

被引:6
作者
Hauschke, D
Pigeot, I
机构
关键词
gold standard design; assay sensitivity; proof of efficacy; relative efficacy; Fieller's confidence interval;
D O I
10.1002/bimj.200510179
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
[No abstract available]
引用
收藏
页码:797 / 798
页数:2
相关论文
共 9 条
[1]  
*COMM MED PROD HUM, 2005, CPMPEWP428002 COMM M
[2]  
*COMM MED PROD HUM, 2005, CPMPEWP215899 COMM M
[3]  
*COMM PROPR MED PR, 2000, CPMPICH36496
[4]  
*COMM PROPR MED PR, 2003, CPMPEWP78801
[5]  
Committee for Proprietary Medicinal Products, 2002, CPMPEWP292201
[6]   Assessment of clinical relevance by considering point estimates and associated confidence intervals [J].
Kieser, M ;
Hauschke, D .
PHARMACEUTICAL STATISTICS, 2005, 4 (02) :101-107
[7]  
Koch Armin, 2004, J Biopharm Stat, V14, P315
[8]   Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo [J].
Pigeot, I ;
Schäfer, J ;
Röhmel, J ;
Hauschke, D .
STATISTICS IN MEDICINE, 2003, 22 (06) :883-899